Maravai Lifesciences Holdings (MRVI) Net Income towards Common Stockholders (2020 - 2026)

Maravai Lifesciences Holdings' Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$6.4 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 87.93% year-over-year to -$6.4 million in Q1 2026; TTM through Mar 2026 was -$184.3 million, a 36.41% increase from a year earlier, with the FY2025 full-year figure at -$230.8 million, up 11.12% from the prior year.
• Net Income towards Common Stockholders grew to -$6.4 million in Q1 2026 per MRVI's latest filing, from -$63.0 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $156.7 million in Q2 2022 and bottomed at -$172.5 million in Q3 2024.
• The 5-year median for Net Income towards Common Stockholders is -$18.4 million (2024), against an average of -$8.5 million.
• Across the five-year window, Net Income towards Common Stockholders surged 94.61% in 2022 and slumped 1582.49% in 2024, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at $87.4 million in 2022, then tumbled by 225.8% to -$110.0 million in 2023, then surged by 58.11% to -$46.1 million in 2024, then plunged by 36.79% to -$63.0 million in 2025, then surged by 89.88% to -$6.4 million in 2026.
• Per Business Quant, the three latest MRVI Net Income towards Common Stockholders figures stand at -$6.4 million (Q1 2026), -$63.0 million (Q4 2025), and -$45.1 million (Q3 2025).